ArticleTranslational gastroenterology and hepatology2026
Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial.
Peter D Block et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.